

# Complement

## Monoclonal Antibodies: Murine Anti-Human SC5b-9 (TCC, neoantigen)

**For Research Use Only. Not for use in Diagnostic Procedures.**

### Background

The Terminal Complement Complex (TCC, SC5b-9) is generated by the assembly of C5 through C9 as a consequence of activation of the complement system by either the classical, lectin or alternative pathway. The membrane attack complex (MAC), a form of TCC, is a stable complex that mediates the irreversible target cell membrane damage associated with complement activation. Complexes formed in the absence of a target membrane bind to naturally occurring regulatory serum proteins, e.g. the S protein, at the C5b-7 stage of assembly forming soluble, non-lytic TCC.

### Specificity

The specificity of the monoclonal antibody was established via a series of immunoassays. First, the antibody was shown by ELISA to bind SC5b-9 and C9 immobilized in microtiter wells, but not to immobilized C3, C5, C6, C7, C8 or S protein. Immobilized C9 is known to express antigenic determinates in common with polymeric C9. Second, free (unbound) SC5b-9, free (unbound) C9 and zymosan-activated human serum were shown (via inhibition EIA) to inhibit the binding of this antibody to immobilized SC5b-9. Subsequently, the antibody was shown to bind complement lysed sheep and rabbit erythrocytes (both of which contain TCC). The antibody therefore binds polymerized C9 present in both SC5b-9 and MAC, the two major forms of TCC.

### Applications

EIA <sup>1</sup>	RIA	IHC <sup>2-4</sup>	WB <sup>4</sup>	FACS <sup>5</sup>
>1:10,000	N/T	>1:1000	>1:1,000	>1:100

N/T = Not tested.

### Specifications

Catalog Number: A239  
 Concentration: 1.0-1.2 mg/ml  
 Purity: ≥ 95% by SDS PAGE  
 Volume/Vial: 100 µl  
 Storage:  
     ≤ 30 Days 2-8 °C  
     > 30 Days ≤ -20 °C  
 Buffer: Borate Buffered Saline  
         (pH 8.4 ± 0.2)  
 Isotype: IgG<sub>2a</sub>k

**Species Cross Reactivity:** Human, baboon, Cynomolgus macaque, Rhesus macaque.

### References

- 1 On file with Quidel Corporation.
- 2 Rogers J. et al. Complement activation by beta-amyloid in alzheimer disease. Proc Natl Acad Sci USA 89(21):10016-10020 (1992).
- 3 Stoltzner, S.E. et al. Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with alzheimers disease. Am J Path 156(2):489-499 (2000).
- 4 Yasojima, K. et al. Human heart generates complement proteins that are upregulated and activated after myocardial infarction. Circ Res 83(8):860-869 (1998).

5 Gemmell, C.H. et al. A flow cytometric immunoassay to quantify adsorption of complement activation products on artificial surfaces. J Biomed Mater Res 37(4):474-480 (1997).

### Ordering and Additional Information

To learn more about this and other Quidel products visit our website [quidel.com](http://quidel.com) or contact Technical Services at 1.800.874.1517

### Related Products

MicroVue SC5b-9 Plus EIA Kit	A020
Monoclonal Anti-Human SC5b-9 biotin labeled	A711
Purified Human C9 Protein	A407

**QUIDEL**<sup>®</sup>  
Specialty Products

RESEARCH TO RAPIDS<sup>®</sup>

**Worldwide Headquarters**  
 10165 McKellar Court  
 San Diego, CA 92121 USA  
[quidel.com](http://quidel.com)

For more information on our products and other Quidel locations, visit our website.  
 800.874.1517 • 408.616.4301 • 858.431.3520 (fax)

0122AI0712D-1 (10/12)